IL142768A0 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity - Google Patents
N-ureidoalkyl-piperidines as modulators of chemokine receptor activityInfo
- Publication number
- IL142768A0 IL142768A0 IL14276899A IL14276899A IL142768A0 IL 142768 A0 IL142768 A0 IL 142768A0 IL 14276899 A IL14276899 A IL 14276899A IL 14276899 A IL14276899 A IL 14276899A IL 142768 A0 IL142768 A0 IL 142768A0
- Authority
- IL
- Israel
- Prior art keywords
- modulators
- ureidoalkyl
- piperidines
- chemokine receptor
- receptor activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Electroluminescent Light Sources (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11271798P | 1998-12-18 | 1998-12-18 | |
US16122199P | 1999-10-22 | 1999-10-22 | |
PCT/US1999/030334 WO2000035452A1 (en) | 1998-12-18 | 1999-12-17 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
IL142768A0 true IL142768A0 (en) | 2002-03-10 |
Family
ID=26810264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14276899A IL142768A0 (en) | 1998-12-18 | 1999-12-17 | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
Country Status (17)
Country | Link |
---|---|
US (1) | US6444686B1 (de) |
EP (1) | EP1161240B1 (de) |
JP (1) | JP2002532427A (de) |
KR (1) | KR20010101287A (de) |
CN (1) | CN1206219C (de) |
AT (1) | ATE302005T1 (de) |
AU (1) | AU770042B2 (de) |
BR (1) | BR9917038A (de) |
CA (1) | CA2347770A1 (de) |
DE (1) | DE69926806D1 (de) |
EA (1) | EA003147B1 (de) |
HK (1) | HK1044282A1 (de) |
IL (1) | IL142768A0 (de) |
NO (1) | NO20012977L (de) |
NZ (1) | NZ511394A (de) |
TR (1) | TR200101859T2 (de) |
WO (1) | WO2000035452A1 (de) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6525069B1 (en) | 1998-12-18 | 2003-02-25 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
US6605623B1 (en) * | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
WO2000035876A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
CA2348923A1 (en) | 1998-12-18 | 2000-06-22 | Dean A. Wacker | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
DE69926919D1 (de) * | 1998-12-18 | 2005-09-29 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
EP1220836A2 (de) | 1999-10-15 | 2002-07-10 | Bristol-Myers Squibb Pharma Company | Benzylcyklohexylamine als modulatoren der chemokin-rezeptor-aktivität |
US6784200B2 (en) | 2000-10-13 | 2004-08-31 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
US6586446B1 (en) | 1999-10-15 | 2003-07-01 | Bristol-Myers Squibb Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
US6897234B2 (en) * | 1999-12-17 | 2005-05-24 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU2001268607A1 (en) | 2000-06-21 | 2002-01-02 | Bristol-Myers Squibb Company | Piperidine amides as modulators of chemokine receptor activity |
IL153123A0 (en) | 2000-06-30 | 2003-06-24 | Bristol Myers Squibb Co | N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same |
KR20030031198A (ko) | 2000-09-29 | 2003-04-18 | 글락소 그룹 리미티드 | 염증 질환 치료용 모르폴린-아세트아미드 유도체 |
KR20030061455A (ko) | 2000-12-19 | 2003-07-18 | 에프. 호프만-라 로슈 아게 | Ccr-3 수용체 길항제로서의 치환된 피롤리딘 |
US6974869B2 (en) | 2001-09-18 | 2005-12-13 | Bristol-Myers Squibb Pharma Company | Piperizinones as modulators of chemokine receptor activity |
ATE370932T1 (de) * | 2001-11-30 | 2007-09-15 | Hoffmann La Roche | Ccr-3-rezeptorantagonisten vii |
DE60221275T2 (de) | 2001-11-30 | 2008-05-08 | F. Hoffmann-La Roche Ag | Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma |
EP1453825A1 (de) * | 2001-11-30 | 2004-09-08 | F. Hoffmann-La Roche Ag | N-ureido-piperidine zur verwendung als ccr-3-rezeptor-antagonisten viii |
US6977265B2 (en) | 2001-11-30 | 2005-12-20 | Roche Palo Alto Llc | Piperidine CCR-3 receptor antagonists |
PL211954B1 (pl) * | 2002-01-11 | 2012-07-31 | Sankyo Co | Związek, kompozycja farmaceutyczna oraz zastosowanie kompozycji farmaceutycznej |
TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
US20060229324A1 (en) * | 2002-10-03 | 2006-10-12 | Akiko Itai | Quinazolin-4-one derivatives |
AU2003296993A1 (en) * | 2002-12-13 | 2004-07-09 | Smithkline Beecham Corporation | Cyclopropyl compounds as ccr5 antagonists |
WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
JP4943837B2 (ja) * | 2003-04-03 | 2012-05-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良インヒビター |
US7498323B2 (en) | 2003-04-18 | 2009-03-03 | Ono Pharmaceuticals Co., Ltd. | Spiro-piperidine compounds and medicinal use thereof |
US7351720B2 (en) * | 2003-06-12 | 2008-04-01 | Bristol-Myers Squibb Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
EP1663966B1 (de) * | 2003-09-15 | 2007-06-20 | Novartis AG | 1,3-disubstituierte azetidinderivate zur verwendung als antagonisten des ccr-3-rezeptors bei der behandlung von entzündlichen und allergischen krankheiten |
CN1856305B (zh) * | 2003-09-26 | 2010-04-28 | 埃科特莱茵药品有限公司 | 用作尾加压素ⅱ拮抗剂的吡啶衍生物 |
US7291744B2 (en) | 2003-11-13 | 2007-11-06 | Bristol-Myers Squibb Company | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity |
SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
KR20110136901A (ko) | 2004-02-24 | 2011-12-21 | 상꾜 가부시키가이샤 | 아미노 알코올 화합물 |
US20090018092A1 (en) | 2004-03-16 | 2009-01-15 | The Regents Of The University Of California | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
KR101231466B1 (ko) | 2004-09-13 | 2013-02-07 | 오노 야꾸힝 고교 가부시키가이샤 | 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는약제 |
WO2006045119A2 (en) * | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
JPWO2006129679A1 (ja) | 2005-05-31 | 2009-01-08 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
US8318931B2 (en) | 2005-10-28 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
KR101331768B1 (ko) | 2005-11-08 | 2013-11-22 | 버텍스 파마슈티칼스 인코포레이티드 | Atp 결합 카세트 수송체의 헤테로사이클릭 조정제 |
ES2407115T3 (es) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compuesto que contiene un grupo básico y uso del mismo |
BRPI0619096A2 (pt) | 2005-12-01 | 2011-09-13 | Hoffmann La Roche | derivados de ácidos vinìlogos |
CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
TW200812582A (en) * | 2006-04-06 | 2008-03-16 | Astrazeneca Ab | Medicaments |
TW200815351A (en) * | 2006-05-02 | 2008-04-01 | Astrazeneca Ab | Novel compounds |
JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
US20090325992A1 (en) | 2006-07-31 | 2009-12-31 | Ono Pharmaceutical Co., Ltd. | Compound having cyclic group bound thereto through spiro binding and use thereof |
US7705034B2 (en) | 2006-10-13 | 2010-04-27 | Hoffmann-La Roche Inc. | Vinylogous acid derivatives |
WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
SG186638A1 (en) | 2007-12-07 | 2013-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
KR20150066608A (ko) | 2007-12-07 | 2015-06-16 | 버텍스 파마슈티칼스 인코포레이티드 | 사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법 |
CA2716109C (en) | 2008-02-28 | 2016-07-19 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as cftr modulators |
GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
US8410139B2 (en) * | 2009-10-07 | 2013-04-02 | Bristol-Myers Squibb Company | Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
TWI549950B (zh) * | 2010-04-07 | 2016-09-21 | 維泰克斯製藥公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧雜環戊烯-5-基)環丙烷甲醯胺基)-3-甲基吡啶-2-基)苯甲酸之固體形式 |
RU2592368C2 (ru) | 2010-04-07 | 2016-07-20 | Вертекс Фармасьютикалз Инкорпорейтед | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ 3-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНУЮ КИСЛОТУ, И ИХ ВВЕДЕНИЕ |
AU2012294448A1 (en) | 2011-08-08 | 2014-03-06 | Boyce Thompson Institute For Plant Research | Small molecule compounds for the control of nematodes |
EP2741752A4 (de) | 2011-08-08 | 2015-04-01 | California Inst Of Techn | Verwendung kleiner nematodenmoleküle |
AU2014349010C1 (en) | 2013-11-12 | 2020-08-06 | Vertex Pharmaceuticals Incorporated | Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases |
JP6618120B2 (ja) | 2014-08-06 | 2019-12-11 | 塩野義製薬株式会社 | TrkA阻害活性を有する複素環および炭素環誘導体 |
JP6494757B2 (ja) | 2014-11-18 | 2019-04-03 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ハイスループット試験高速液体クロマトグラフィーを行うプロセス |
US10640495B2 (en) | 2015-07-07 | 2020-05-05 | Shionogi & Co., Ltd. | Heterocycle derivatives having TrkA inhibitory activity |
JP6898043B2 (ja) | 2016-02-04 | 2021-07-07 | 塩野義製薬株式会社 | TrkA阻害活性を有する含窒素複素環および炭素環誘導体 |
AU2017234042B2 (en) | 2016-03-17 | 2020-11-19 | F. Hoffmann-La Roche Ag | 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of TAAR |
MA46062A (fr) | 2016-08-25 | 2019-07-03 | Boyce Thompson Institute For Plant Res | Traitement par ascaroside de l'oesophagite à éosinophiles |
WO2018119395A1 (en) * | 2016-12-23 | 2018-06-28 | Aquinnah Pharmaceuticals, Inc. | Compouns, compositions and methods of use |
CA3140784A1 (en) | 2019-05-17 | 2020-11-26 | California Institute Of Technology | Ascaroside derivatives and methods of use |
IL308659A (en) * | 2021-05-26 | 2024-01-01 | Sumitomo Pharma Co Ltd | The history of phenylurea |
CA3220039A1 (en) | 2021-06-14 | 2022-12-22 | Jr. David St. Jean | Urea derivatives which can be used to treat cancer |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3461120A (en) | 1965-09-27 | 1969-08-12 | Sterling Drug Inc | N-((1-piperidyl)-lower-alkyl)-n-((3-,2-,and 1-indolyl)-lower-alkyl) amines |
GB8816365D0 (en) * | 1988-07-08 | 1988-08-10 | Pfizer Ltd | Therapeutic agents |
GB9206757D0 (en) | 1992-03-27 | 1992-05-13 | Ferring Bv | Novel peptide receptor ligands |
WO1994022846A1 (en) | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
DK60893D0 (da) | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Piperidinderivater, deres fremstilling og anvendelse |
DK60693D0 (da) | 1993-05-26 | 1993-05-26 | Novo Nordisk As | Kemiske forbindelser, deres fremstilling og anvendelse |
CA2180746A1 (en) | 1994-01-13 | 1995-07-20 | Raymond Baker | Gem-disubstituted azacyclic tachykinin antagonists |
AU5499396A (en) * | 1995-04-05 | 1996-10-23 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Use of substituted piperidine or pyrrolidine compounds for t reating sigma-receptor modulated disorders |
US5668151A (en) | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
CA2237384A1 (en) | 1995-11-13 | 1997-05-22 | The Albany Medical College | Analgesic compounds and uses thereof |
DE69621831T2 (de) | 1995-12-18 | 2003-01-02 | Fujisawa Pharmaceutical Co | Piperazinderivative als tachykinin antagonisten |
AU712504B2 (en) | 1996-01-30 | 1999-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5688955A (en) * | 1996-03-08 | 1997-11-18 | Adolor Corporation | Kappa agonist compounds and pharmaceutical formulations thereof |
JP2001519766A (ja) | 1996-04-03 | 2001-10-23 | メルク エンド カンパニー インコーポレーテッド | ファルネシルタンパク質トランスフェラーゼの阻害剤 |
WO1998025604A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
WO1998031364A1 (en) | 1997-01-21 | 1998-07-23 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
MY133223A (en) | 1998-06-08 | 2007-10-31 | Schering Corp | Neuropeptide y5 receptor antagonists |
SE9802209D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
-
1999
- 1999-12-17 US US09/466,442 patent/US6444686B1/en not_active Expired - Lifetime
- 1999-12-17 BR BR9917038-8A patent/BR9917038A/pt not_active IP Right Cessation
- 1999-12-17 IL IL14276899A patent/IL142768A0/xx unknown
- 1999-12-17 NZ NZ511394A patent/NZ511394A/xx unknown
- 1999-12-17 WO PCT/US1999/030334 patent/WO2000035452A1/en not_active Application Discontinuation
- 1999-12-17 DE DE69926806T patent/DE69926806D1/de not_active Expired - Lifetime
- 1999-12-17 KR KR1020017007631A patent/KR20010101287A/ko not_active Application Discontinuation
- 1999-12-17 CA CA002347770A patent/CA2347770A1/en not_active Abandoned
- 1999-12-17 EP EP99963107A patent/EP1161240B1/de not_active Expired - Lifetime
- 1999-12-17 JP JP2000587772A patent/JP2002532427A/ja active Pending
- 1999-12-17 TR TR2001/01859T patent/TR200101859T2/xx unknown
- 1999-12-17 AT AT99963107T patent/ATE302005T1/de not_active IP Right Cessation
- 1999-12-17 AU AU19406/00A patent/AU770042B2/en not_active Ceased
- 1999-12-17 CN CNB998145394A patent/CN1206219C/zh not_active Expired - Fee Related
- 1999-12-17 EA EA200100678A patent/EA003147B1/ru not_active IP Right Cessation
-
2001
- 2001-06-15 NO NO20012977A patent/NO20012977L/no not_active Application Discontinuation
-
2002
- 2002-08-09 HK HK02105845.4A patent/HK1044282A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CN1335771A (zh) | 2002-02-13 |
NO20012977D0 (no) | 2001-06-15 |
ATE302005T1 (de) | 2005-09-15 |
AU770042B2 (en) | 2004-02-12 |
JP2002532427A (ja) | 2002-10-02 |
US6444686B1 (en) | 2002-09-03 |
AU1940600A (en) | 2000-07-03 |
CN1206219C (zh) | 2005-06-15 |
BR9917038A (pt) | 2002-04-02 |
EP1161240B1 (de) | 2005-08-17 |
EP1161240A1 (de) | 2001-12-12 |
WO2000035452A1 (en) | 2000-06-22 |
EP1161240A4 (de) | 2002-04-03 |
TR200101859T2 (tr) | 2001-12-21 |
DE69926806D1 (de) | 2005-09-22 |
HK1044282A1 (zh) | 2002-10-18 |
CA2347770A1 (en) | 2000-06-22 |
NZ511394A (en) | 2003-07-25 |
EA200100678A1 (ru) | 2001-12-24 |
NO20012977L (no) | 2001-08-20 |
EA003147B1 (ru) | 2003-02-27 |
KR20010101287A (ko) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL142768A0 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
MXPA02012712A (es) | N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas. | |
AU3126600A (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
WO2003024401A3 (en) | Piperizinones as modulators of chemokine receptor activity | |
WO2001098268A3 (en) | Piperidine amides as modulators of chemokine receptor activity | |
WO2001028987A8 (en) | Benzylcycloalkyl amines as modulators of chemokine receptor activity | |
AU2002220715A1 (en) | Indolsulfonyl compounds useful in the treatment of cns disorders | |
WO2000035919A3 (en) | Quinoline derivatives | |
ZA9710796B (en) | Oxyiminopregnanecarbolactones. | |
WO2002072536A8 (en) | Urea derivatives having vanilloid receptor (vr1) antagonist activity | |
WO2002050019A3 (en) | Diamines as modulators of chemokine receptor activity | |
GB0111186D0 (en) | Novel compounds | |
WO2001098270A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
AU5186799A (en) | Peptides of il-2 and derivatives thereof and their use as therapeutic agents | |
WO2001098269A3 (en) | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity | |
WO2004071449A3 (en) | Lactams as modulators of chemokine receptor activity | |
TW200640944A (en) | VGF polypeptides and methods of treating VGF-related disorders | |
AU2351095A (en) | Benzimidazole derivatives having dopaminergic activity | |
AU1028601A (en) | Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity | |
MY120237A (en) | Method for the synthesis of quinoline derivatives | |
MXPA02000680A (es) | Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf. | |
AU2002227895A1 (en) | Sulphonamides for the treatment of central nervous system diseases | |
AU3284000A (en) | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis | |
WO2005048932A3 (en) | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | |
AU2002365288A1 (en) | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases |